Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.51 |
| ▸ | GCGR | P47871 | 3/20 | 0.51 |
| ▸ | RIPK3 | Q9Y572 | 5/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6583283 | 1.00 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL6590838 | 0.89 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL5095878 | 0.79 | RIPK3 (0.57) | MAPK14GCGRRIPK3 | |
| SCHEMBL1127766 | 0.77 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL6587012 | 0.77 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL5091878 | 0.75 | TDP1 (0.53) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL5858720 | 0.75 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL7139249 | 0.75 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL6581107 | 0.75 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL6509449 | 0.73 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11RIPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132544-B2 | Process for the preparation of tetrasubstituted imidazole derivatives and novel crystalline structures thereof | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-7067671-B2 | Process for the preparation of tetrasubstituted imidazole derivatives and novel crystalline structures thereof | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-20060030712-A1 | Process for the preparation of tetrasubstituted imidazole derivatives and novel crystalline structures thereof | ZHONG HUA | 2006-02-09 | — | — | US | disclosed |
| EP-1508569-A2 | Process for the preparation of tetrasubstituted imidazole derivatives and novel crystalline structures thereof | Ortho-McNeil Pharmaceutical, Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| EP-1506966-A2 | Process for the preparation of tetrasubstituted imidazole derivatives and novel crystaline structures thereof | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20030045723-A1 | Process for the preparation of tetrasubstituted imidazole derivatives and novel crystalline structures thereof | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045723-A1 | Process for the preparation of tetrasubstituted imidazole derivatives and novel crystalline structures thereof | CYP4B1, IPO4, RPS4Y1 | MAPK14 2413/4885MAPK13 2524/4885MAPK12 2719/4885 |
| US-20060030712-A1 | Process for the preparation of tetrasubstituted imidazole derivatives and novel crystalline structures thereof | CYP4F3, CYP4F2, CYP4B1 | MAPK14 2729/4885MAPK13 3001/4885MAPK12 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.